The stock of a one time 'Busted IPO' and 'Tier 4' biotech concern continued its impressive rally last week and is up again Monday in early trade.
The stock is up more than 80% over the past six months as can be seen from the chart above. Given this, it is time to revisit this name and outline a potential Buy-Write option strategy in the paragraphs below.
Company Overview:
Karyopharm Therapeutics (KPTI) is Massachusetts-based clinical-stage pharmaceutical company just outside Boston. The firm is focused on discovering, developing, and commercializing novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm Therapeutics has a market capitalization of just north of $1.1 billion and trades just over $19.00 a share.
